Xenofon Baraliakos
Xenofon Baraliakos is an expert in Rheumatology at Universitätsklinik Marien Hospital Herne (Germany). As of November 2026, ScienceLeadR ranks Xenofon Baraliakos in the top 1% of experts worldwide for Ankylosis, Axial Spondyloarthritis and Spondylarthritis. Xenofon Baraliakos has authored 959 publications, the most recent in 2026, and is an investigator in 43 clinical trials, 5 of them ongoing. SLR score: 4,331 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Dermatology - Internal Medicine - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026Ruhr-Universität Bochum
- 2026
Rheumazentrum Ruhrgebiet
2004 - 2026
Ruhr University Bochum
2005 - 2026
Universitätsklinik Marien Hospital Herne
2012 - 2026
St. Josef-Hospital
2022 - 2026
Number : 959
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 43
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| EAST 1 (ERAP inhibition in Axial Spondyloarthritis Trial 1) 2025-521315-39-00 — axial spondyloarthritis | Phase 1 | Recruiting | 2025 |
| Study of CC 97540 (BMS 986353) CD19 CAR T Cells in Participants with Active SLE Despite Immunosuppressants (Breakfree SLE) 2024-519278-37-00 — cells, glucocorticoids, lupus nephritis, immunosuppressive agents, lupus erythematosus, systemic, nephritis, car-t cell | Phase 2 | Active not recruiting | 2025 |
| Effects of IL 23 inhibition in patients with very early axial spondyloarthritis evidence for a true disease modification 2023-507718-28-00 — interleukin-23, axial spondyloarthritis | Phase 2 | Active not recruiting | 2024 |
| Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis 2024-513213-13-00 — anti-inflammatory agents, non-steroidal, therapeutics, biosimilar pharmaceuticals, axial spondyloarthritis | Phase 4 | Recruiting | 2025 |
| A Study of Guselkumab Administered Subcutaneously in Bio naive Participants With Active Psoriatic Arthritis Axial Disease NCT04929210 — injections, arthritis, psoriatic, safety, arthritis, injections, subcutaneous | Phase 4 | Active not recruiting | 2021 |
LeadR Networks
Main global connection map